At Persephone, we harness the power of science and nature to create trusted products that reimagine infant and patient health.
Co-founded in 2017 by synthetic biologists Stephanie Culler, Ph.D. and Steve Van Dien, Ph.D., our work is grounded in research, from decoding the infant microbiome to developing next generation probiotics and disease-preventing therapeutics. This includes our new synbiotic for infants and toddlers, designed to support gut and immune health from the very beginning.
In December 2021, emerging insights revealed an opportunity to address infant gut dysbiosis, a condition increasingly linked to adverse long-term health outcomes. Persephone became dedicated to solving this global health crisis, leading to the launch of the My Baby Biome study in August 2022.
Company Details
- Employees
- 27
- Founded
- -
- Address
- 10835 Road To The Cure,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://persephone.bio/
- Keywords
- Omics Analysis, Metabolism, Machine Learning, Synthetic Biology, Systems Biology, Oncology, Infant Health.
- HQ
- San Diego, California
Persephone Biosciences Questions
Persephone Biosciences's website is https://persephone.bio/
Persephone Biosciences's LinkedIn profile is https://www.linkedin.com/company/persephone-biosciences
Persephone Biosciences has
27 employees.
View email and phone details for 27
employees at Persephone Biosciences.
Persephone Biosciences's industry is
Biotechnology Research
Persephone Biosciences's top competitors are
Nabla Bio,
Floré By Sun Genomics,
Terremoto Biosciences,
Slingshot Biosciences,
Geno,
Persephoni Bio,
Resbiotic,
Second Genome Inc.,
Seed Health,
Manifold Bio.
Persephone Biosciences's categories are Biotechnology Research
Persephone Biosciences's founding year is 2017
